The results of a controlled clinical trial that used high doses of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer are reported. Two treatment regimens were used: regimen A, 500 mg daily with a total dose of 30 g; regimen B, 1,000 mg daily with a total dose of 60 g. The overall response rates were similar, with no statistically significant difference between the two treated groups. Regimen A (lower dosage group) reached a remission rate of 44%, whereas regimen B (higher dosage group) had a remission rate of 41%. The mean duration of response was 8 months with regimen A and 9 months with regimen B. The advantages of the lower dosage regimen as opposed to the higher dosage regimen of MPA in the treatment of advanced breast cancer are discussed.
Get full access to this article
View all access options for this article.
References
1.
AmadoriD.RavaioliA.BarbantiF.: L'impiego del medrossiprogesterone acetato ad alti dosaggi nella terapia palliativa del carcinoma mammario in fase avanzata.Minerva Med., 67: 1–14, 1976.
2.
BonteJ.: Radium therapy and medroxyprogesterone acetate treatment in the management of primary and recurrent or metastatic uterine adenocarcinoma. pp. 203–211. Proceedings of the Symposium Endometrial Cancer, St. Thomas Hospital, London, 1971.
3.
BucalossiP.CataniaV.GennariL.: Trattamento ormonico del carcinoma mammario diffuso con un progestativo di sintesi: il 6-alfa-metil-17-alfa-acetossi-progesterone.Minerva Chir., 18: 358–366, 1963.
4.
BouffiouxC. H.: Treatment of prostatic cancer with progestinic agents.International Congress on Prostatic Cancer, Leeds, July 6–9, 1976.
5.
Cooperative Breast Cancer Group: Protocol I - A cooperative study to evaluate experimental steroids in the therapy of advanced breast carcinoma.Cancer Chemother. Rep.11: 130–136, 1961.
6.
Cooperative Breast Cancer Group: Results of studies of the Cooperative Breast Cancer Group - 1961–1963.Cancer Chemother. Rep. (Suppl. I), 41: 1, 1964.
7.
Cooperative Breast Cancer Group: Testosterone propionate therapy in breast cancer.JAMA, 188: 1069–1074, 1964.
8.
DenisL.DeclercqC.: Progestogens in Prostatic Cancer.International Congress on Prostatic Cancer, Leeds, July 6–9, 1976.
9.
DogliottiG. C.GavostoF.MolinattiG. M.: Trattamento del cancro avanzato della mammella con progestativi di sintesi.Minerva Med., 81: 4283–4296, 1968.
10.
GoldenbergI. S.WatersM. N.RavdinR. S.AnsfieldF. J.SegaloffA.: Androgenic therapy for advanced breast cancer in women. A report of the Cooperative Breast Cancer Group.JAMA, 223: 1267–1268, 1973.
11.
LonguevilleJ.MaisinH.: Combined therapy with adriamycin-DNA, vincristine and medroxyprogesterone acetate in metastatic breast cancer.Adriamycin Review, 4: 260–267, 1975.
12.
MartinoG.VentafriddaV.: Effetto antalgico dell'alcoolizzazione ipofisaria, del medrossiprogesterone acetato ad alte dosi e della loro associazione nel carcinoma mammario in fase avanzata.Tumori, 62: 93–98, 1976.
13.
MuggiaF. M.CassilethP. A.OchoaM.Jr., FlatowF. A.GellhornA.HymangA.: Treatment of breast cancer with medroxyprogesterone acetate.Ann. Intern. Med., 68: 328–337, 1968.
14.
PannutiF.MartoniA.PollutriE.CameraP.LenazG. R.: Medroxyprogesterone acetate (MAP): Effects of massive doses in advanced breast cancer.IRCS Med. Sci., 2: 1605, 1974.
15.
PannutiF.MartoniA.LenazG. R.PianaE.NanniP.: Management of advanced breast cancer with medroxyprogesterone acetate (MAP, F.I.5837, F.I.7001, NSC 26386) in high doses, pp. 243–265. In: Functional Exploration in Senology.European Press, Ghent (Belgium), 1976.
16.
PannutiF.MartoniA.PollutriE.CameraP.LosinnoF.GiustiH.: Massive dose progestational therapy in oncology (Medroxyprogesterone). Preliminary results. Acts of the 4th Symposium on the Locoregional Treatment of Tumors. St. Vincent, 1973.Panminerva Med., 18: 129–136, 1976.
17.
Progress in the Treatment of Advanced Breast Cancer.Medical Staff Conference (University of California, San Francisco).Clin. Med., 111: 38–45, 1969.
18.
StollB. A.: Endocrine therapy in malignant disease, pp. 182–186. W. B. Saunders, 1972.
